0.35 to 0.87), and long-term mortality rates that were no different (22.7% vs. 20.5% at 2.9 years; HR: 1.07; 95% CI: 0.92 to 1.24), than those of patients who had undergone CABG. For the group with CKD stage 5 on hemodialysis, however, the study found that patients treated with EES had higher long-term mortality rates (54.3% vs. 39.1%; HR: 2.02; 95% CI: 1.40 to 2.93) than did patients treated with CABG.
Because the current study is a rigorous analysis (5), a finding of a narrowed mortality difference between PCI and CABG for patients with CKD stage III or IV is newsworthy. To put the results of the study into From the Munroe Regional Medical Center, Ocala, Florida. Dr. Bittl has reported that he has no relationships relevant to the contents of this paper to disclose. 
